Torray Investment Partners LLC Buys Shares of 97,802 Syndax Pharmaceuticals, Inc. $SNDX

Torray Investment Partners LLC bought a new stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 97,802 shares of the company’s stock, valued at approximately $2,055,000.

A number of other institutional investors also recently made changes to their positions in SNDX. AQR Capital Management LLC raised its position in shares of Syndax Pharmaceuticals by 478.8% in the 1st quarter. AQR Capital Management LLC now owns 377,444 shares of the company’s stock valued at $4,637,000 after purchasing an additional 312,231 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Syndax Pharmaceuticals by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,842 shares of the company’s stock valued at $705,000 after purchasing an additional 3,094 shares in the last quarter. Caxton Associates LLP acquired a new position in shares of Syndax Pharmaceuticals in the 1st quarter valued at approximately $257,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Syndax Pharmaceuticals by 18.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 200,696 shares of the company’s stock valued at $2,466,000 after purchasing an additional 30,596 shares in the last quarter. Finally, Legal & General Group Plc raised its position in shares of Syndax Pharmaceuticals by 4.9% in the 2nd quarter. Legal & General Group Plc now owns 84,575 shares of the company’s stock valued at $792,000 after purchasing an additional 3,937 shares in the last quarter.

Insiders Place Their Bets

In other news, CFO Keith A. Goldan sold 3,410 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $21.03, for a total transaction of $71,712.30. Following the transaction, the chief financial officer directly owned 140,429 shares of the company’s stock, valued at approximately $2,953,221.87. This trade represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael A. Metzger sold 17,159 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $21.03, for a total value of $360,853.77. Following the transaction, the chief executive officer directly owned 491,690 shares of the company’s stock, valued at $10,340,240.70. This represents a 3.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 30,063 shares of company stock worth $628,332 over the last three months. Corporate insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

SNDX has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a research report on Friday, March 27th. Citigroup upped their price target on Syndax Pharmaceuticals from $51.00 to $57.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Mizuho dropped their price target on Syndax Pharmaceuticals from $45.00 to $43.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 31st. Stifel Nicolaus set a $45.00 price target on Syndax Pharmaceuticals in a research report on Friday, February 27th. Finally, Wall Street Zen raised Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, March 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Syndax Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $40.33.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX traded down $0.26 during trading hours on Thursday, reaching $21.82. 287,976 shares of the company’s stock traded hands, compared to its average volume of 1,356,186. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of -6.63 and a beta of 0.41. The company has a debt-to-equity ratio of 5.32, a current ratio of 4.40 and a quick ratio of 4.12. Syndax Pharmaceuticals, Inc. has a twelve month low of $8.58 and a twelve month high of $25.59. The business’s fifty day simple moving average is $22.97 and its two-hundred day simple moving average is $20.18.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.14). The business had revenue of $68.73 million for the quarter, compared to analyst estimates of $64.75 million. Syndax Pharmaceuticals had a negative net margin of 165.37% and a negative return on equity of 206.62%. Syndax Pharmaceuticals’s revenue for the quarter was up 792.6% on a year-over-year basis. During the same period last year, the business posted ($1.10) earnings per share. Analysts predict that Syndax Pharmaceuticals, Inc. will post -1.65 earnings per share for the current year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.